Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune has advanced its efforts to develop CAT-354, a potential treatment for patients with asthma, with the start of two new trials with a monoclonal antibody targeting interleukin-13.
Subscribe to our email newsletter
One of the studies is a Phase II clinical trial to assess the potential of the anti-IL-13 monoclonal antibody (MAb) in patients with uncontrolled asthma despite optimal treatment. The trial is designed to assess the effects of CAT-354 on airway hyperresponsiveness in patients with uncontrolled asthma. This randomized, double-blind, placebo-controlled study has started in Europe and Australia.
The company has also begun dosing patients in the first US based clinical trial of the antibody, a Phase I study to assess pharmacokinetics in healthy adult patients. The is designed to compare the pharmacokinetics of the antibody when administered via subcutaneous injection versus intravenous infusion in healthy patients. This randomized, open-label, study in healthy male patients marks the first clinical trial to assess the subcutaneous administration of CAT-354, as previous studies have used intravenous infusion administration.
Barbara White, vice president, clinical development, inflammatory disease at MedImmune, said: “Initiating our clinical work in the US is also an important step in bolstering the depth of data we are gathering for this potential asthma treatment.”